A recent study published in the journal Science Direct suggests that lymph node dissection (lymphadenectomy) in patients with non-metastatic renal cell carcinoma (RCC) at high risk of recurrence/spread could be used to identify patients who are most likely to benefit from adjuvant therapy. In the study, the researchers retrospectively assessed the progression of the disease in […]
A recent study, published in the International Journal of Urology, has identified two potential biomarkers for the presence of malignant small renal masses in the urine. The study investigated aquaporin 1 and perilipin 2 to determine if these biomarkers were predictive of malignancy. During the study with 57 patients, the presence of aquaporin 1 and […]
The following paper was presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Cytoreductive nephrectomy (CN) is defined as the surgical removal of the primary renal cell carcinoma (RCC) tumour before starting systemic therapy. The following paper from medical oncologist Dr Lauren Harshman, Dana-Farber Cancer Institute, Boston, USA, suggests that this is an […]
Cancer Research UK and the Greater Manchester Health and Social Care Partnership has produced a report suggesting a new system for reimbursement of cancer drugs by the NHS. The report suggests that paying for cancer drugs based on how well they work in practice could help patients get new treatments faster. This new flexible system, […]
This observation study involved 450 patients with renal cell carcinoma (RCC) and was conducted via social media and patient networking platforms. The survey was designed to investigate frustration points associated with the care of RCC patients. Overall, 71.5% reported frustration, including emotional (48.4%) and practical (23.1%). The most common points of frustration included fear of […]
The following interviews with kidney cancer experts were recorded by Practice Update and UroTodayat the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Pembrolizumab and axitinib as first-line therapy Key data from ASCO GU 2019 on mRCC Frontline RCC treatment from ASCO GU 2019: Practice implications Pembrolizumab for non-clear cell RCC […]
New 30-month survival data from the CheckMate 214 study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Additional 30-month follow-up data from the phase 3 CheckMate 214 trial confirms the survival benefit of the nivolumab plus ipilimumab combination over sunitinib as a first-line treatment for patients […]
The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Ignacio Durán, of the Hospital Universitario Marqués de Valdecilla in Spain, presented new results from the phase 3 METEOR trial showing that patients with advanced renal cell carcinoma (RCC) treated with cabozantinib […]
The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Toni Choueiri from the Dana-Farber Cancer Institute and Harvard Medical School in Boston, USA, presented updated results from the JAVELIN Renal 101 clinical trial. The results showed that treatment with a […]
The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Nicholas Vogelzang of the Comprehensive Cancer Centers of Nevada, Las Vegas, and colleagues presented updated safety data and efficacy of nivolumab in patients with non-clear cell renal cell carcinoma (RCC) in […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
